Autologous haematopoiesis stem cell transplantation (AHSCT) for treatment-refractory autoimmune diseases in children

被引:1
|
作者
Satirer, Oezlem [1 ,2 ]
Henes, Joerg C. [3 ,4 ]
Doering, Michaela [5 ]
Lesk, Till [6 ]
Benseler, Susanne [7 ,8 ]
Kuemmerle-Deschner, Jasmin Beate [1 ,2 ]
机构
[1] Univ Klinikum Tubingen, Dept Paediat, Tubingen, Baden Wurttembe, Germany
[2] Univ Klinikum Tubingen, Autoinflammat Reference Ctr Tuebingen arcT, Tubingen, Baden Wurttembe, Germany
[3] Univ Klinikum Tubingen, Ctr Interdisciplinary Clin Immunol Rheumatol & Aut, Tubingen, Baden Wurttembe, Germany
[4] Univ Klinikum Tubingen, Dept Internal Med Oncol Haematol Immunol & Rheumat, Tubingen, Baden Wurttembe, Germany
[5] Univ Tubingen, Pediat Hematol & Oncol, Tubingen, Baden Wurttembe, Germany
[6] Univ Klinikum Tubingen, Tubingen, Baden Wurttembe, Germany
[7] Alberta Childrens Hosp Res Inst, Rheumatol, Calgary, AB, Canada
[8] Childrens Hlth Ireland, Dublin, Ireland
来源
RMD OPEN | 2024年 / 10卷 / 03期
关键词
Treatment; Autoimmune Diseases; Hematopoietic Stem Cell Transplantation; JUVENILE IDIOPATHIC ARTHRITIS; CAR T-CELLS; SYSTEMIC-SCLEROSIS; ACTIVITY CRITERIA; INTERNATIONAL CONSENSUS; ETANERCEPT; GUIDELINES; BLOOD; IMMUNOTHERAPY; MULTICENTER;
D O I
10.1136/rmdopen-2024-004381
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives To evaluate the long-term effectiveness and safety of autologous haematopoiesis stem cell transplantation (AHSCT) for severe, refractory autoimmune diseases in paediatric patients.Methods A single-centre study of consecutive children and adolescents with refractory autoimmune diseases undergoing AHSCT was performed. Demographics, clinical, laboratory features, pre-AHSCT medications, disease activity and functional status were captured. The primary outcome was progression-free survival, secondary outcomes included overall survival, disease-specific treatment responses, disease activity at the last follow-up and AHSCT safety.Results The study included seven patients: two systemic sclerosis, one pansclerotic morphoea, one eosinophilic fasciitis, one juvenile dermatomyositis and two patients with systemic juvenile idiopathic arthritis; four women, three men median age at AHSCT of 10 years (7-19), median follow-up post-AHSCT of 17 years. Median progression-free survival and overall survival was 4.2 years (95% CI: 0.98 to 8.3) and 17 years (95% CI: 11.8 to 22.1), respectively. Progression-free survival rates at 1 and 2 years post-AHSCT were 100% and 77%, respectively. All children survived. All patients are in clinical remission, only four require ongoing immunotherapy. Safety: Three experienced infections, including HHV6, Candida and Ralstonia sepsis; one developed a systemic inflammatory response syndrome; two new onset secondary autoimmune diseases including autoimmune haemolytic anaemia, Graves' disease and one was found to have a breast fibroadenoma. Treatment toxicity: one cyclophosphamide-associated transient renal failure and pericardial effusion, one patient with amenorrhoea/infertility.Conclusions AHSCT was an effective and safe approach for children and adolescents with treatment-refractory autoimmune diseases. The indication and timing of transplantation requires a careful consideration and a multidisciplinary approach.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 50 条
  • [41] Stem cell transplantation for rheumatic autoimmune diseases
    Thomas Hügle
    Jacob M van Laar
    Arthritis Research & Therapy, 10
  • [42] Hematopoietic stem cell transplantation in autoimmune diseases
    Albarracin, Flavio
    Lopez Meier, Maria Jose
    Naswetter, Gustavo
    Longoni, Hector
    MEDICINA-BUENOS AIRES, 2008, 68 (02) : 153 - 163
  • [43] Haemopoietic stem cell transplantation for autoimmune diseases
    Snowden, JA
    Brooks, PM
    Biggs, JC
    BRITISH JOURNAL OF HAEMATOLOGY, 1997, 99 (01) : 9 - 22
  • [44] Autologous stem cell transplantation in scleroderma
    Farge, Dominique
    Abdallah, Nassim Ait
    Marjanovic, Zora
    Del Papa, Nicoletta
    PRESSE MEDICALE, 2021, 50 (01):
  • [45] Remission of psoriasis after allogeneic, but not autologous, hematopoietic stem-cell transplantation
    Kaffenberger, Benjamin H.
    Wong, Henry K.
    Jarjour, Wael
    Andritsos, Leslie A.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 68 (03) : 489 - 492
  • [46] Cell Based Treatment of Autoimmune Diseases in Children
    Jones, Olcay Y.
    McCurdy, Deborah
    FRONTIERS IN PEDIATRICS, 2022, 10
  • [47] Haematopoietic stem cell transplantation for autoimmune diseases
    Swart, Joost F.
    Delemarre, Eveline M.
    van Wijk, Femke
    Boelens, Jaap-Jan
    Kuball, Jurgen
    van Laar, Jacob M.
    Wulffraat, Nico M.
    NATURE REVIEWS RHEUMATOLOGY, 2017, 13 (04) : 244 - 256
  • [48] Autologous stem cell transplantation in autoimmune and rheumatic diseases: from the molecular background to clinical applications
    Szodoray, P.
    Varoczy, L.
    Szegedi, G.
    Zeher, M.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2010, 39 (01) : 1 - 11
  • [49] Tolerance regeneration by T regulatory cells in autologous haematopoietic stem cell transplantation for autoimmune diseases
    Hendrawan, Kevin
    Visweswaran, Malini
    Ma, David D. F.
    Moore, John J.
    BONE MARROW TRANSPLANTATION, 2020, 55 (05) : 857 - 866
  • [50] Autologous Hematopoietic Stem Cell Transplantation for Autoimmune Disease-Is It Now Ready for Prime Time?
    Atkins, Harold L.
    Muraro, Paolo A.
    van Laar, Jacob M.
    Pavletic, Steven Z.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (01) : S177 - S183